Literature DB >> 36178661

Identification of Gravida Serum Biomarkers for Noninvasive Prenatal Diagnosis Fetal Congenital Heart Disease.

Yi Xia1, Lin Cheng1, Jie Duan1,2, Jianhong Ma1,2, Yuanzhen Zhang3,4.   

Abstract

Congenital heart disease (CHD) is well established as the most common congenital defect worldwide. Given the lack of biomarkers available, we aimed to identify new biomarkers for the noninvasive prenatal diagnosis of fetal CHD. This study used data-independent acquisition (DIA) to explore potential protein biomarkers that co-expressed in gravida serum (GS) and fetal amniotic fluid (AF). Next, parallel reaction monitoring (PRM), enzyme-linked immunosorbent assay (ELISA), receiver operating characteristic curve (ROC) analysis, and the immunohistochemistry (IHC) were performed to validate the potential biomarkers. Based on DIA and PRM proteomics and bioinformatics results, we identified POSTN and PAPPA in GS as candidate biomarkers. Their differential expression during ELISA and IHC were generally consistent with our proteomics results. POSTN combined with PAPPA in GS yield a good diagnose fetal CHD with sensitivity of 83.9%, specificity of 73.9%, and an area under curve (AUC) of 0.842. This is the first study showing that POSTN in GS and AF is associated with fetal CHD. POSTN and PAPPA have huge prospects for application as potential biomarkers in the noninvasive prenatal diagnosis of fetal CHD. Congenital heart disease (CHD) is well-established as the most common congenital defect worldwide. Given the lack of biomarkers available, we aimed to identify new biomarkers for the noninvasive prenatal diagnosis of fetal CHD. We used data independent acquisition (DIA) to explore potential protein biomarkers that co-expressed in gravida serum (GS) and fetal amniotic fluid (AF). Next, parallel reaction monitoring (PRM), enzyme-linked immunosorbent assay (ELISA), receiver operating characteristic curve (ROC) analysis, and the immunohistochemistry (IHC) were performed to validate the potential biomarkers. Based on DIA and PRM proteomics and bioinformatics results, we identified POSTN and PAPPA in GS as candidate biomarkers. Their differential expression during ELISA and IHC were generally consistent with our proteomics results. POSTN combined with PAPPA in GS yield a good diagnose fetal CHD with sensitivity of 83.9 %, specificity of 73.9%, and an area under curve (AUC) of 0.842. This is the first study showing that POSTN in GS and AF is associated with fetal CHD. POSTN and PAPPA have huge prospects for application as potential biomarkers in the noninvasive prenatal diagnosis of fetal CHD.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarkers; Congenital heart disease; PAPPA; POSTN; Prenatal diagnosis; Proteomics

Year:  2022        PMID: 36178661     DOI: 10.1007/s12265-022-10301-5

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   3.216


  20 in total

1.  Periostin as a novel biomarker of cardiovascular disease: A systematic evidence landscape of preclinical and clinical studies.

Authors:  Md Azharuddin; Mohammad Adil; Pinaki Ghosh; Prem Kapur; Manju Sharma
Journal:  J Evid Based Med       Date:  2019-11

2.  Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase.

Authors:  Jonathan T Butcher; Russell A Norris; Stanley Hoffman; Corey H Mjaatvedt; Roger R Markwald
Journal:  Dev Biol       Date:  2006-10-04       Impact factor: 3.582

3.  Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development.

Authors:  Cheryl A Conover; Laurie K Bale; Michael T Overgaard; Edward W Johnstone; Ulla H Laursen; Ernst-Martin Füchtbauer; Claus Oxvig; Jan van Deursen
Journal:  Development       Date:  2004-03       Impact factor: 6.868

4.  Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart.

Authors:  Paige Snider; Robert B Hinton; Ricardo A Moreno-Rodriguez; Jian Wang; Rhonda Rogers; Andrew Lindsley; Fang Li; David A Ingram; Donald Menick; Loren Field; Anthony B Firulli; Jeffery D Molkentin; Roger Markwald; Simon J Conway
Journal:  Circ Res       Date:  2008-02-22       Impact factor: 17.367

Review 5.  Pregnancy-associated plasma protein-A in atherosclerosis: Molecular marker, mechanistic insight, and therapeutic target.

Authors:  Xiao-Hua Yu; Lin-Hao He; Jia-Hui Gao; Da-Wei Zhang; Xi-Long Zheng; Chao-Ke Tang
Journal:  Atherosclerosis       Date:  2018-10-09       Impact factor: 5.162

Review 6.  Periostin in cardiovascular disease and development: a tale of two distinct roles.

Authors:  Natalie M Landry; Smadar Cohen; Ian M C Dixon
Journal:  Basic Res Cardiol       Date:  2017-11-03       Impact factor: 17.165

7.  Periostin Expression is Altered in Aortic Valves in Smad6 Mutant Mice.

Authors:  Yukiko Sugi; Michael J Kern; Roger R Markwald; Jessica L Burnside
Journal:  J Neonatal Biol       Date:  2012-01-21

8.  Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies.

Authors:  Yingjuan Liu; Sen Chen; Liesl Zühlke; Graeme C Black; Mun-Kit Choy; Ningxiu Li; Bernard D Keavney
Journal:  Int J Epidemiol       Date:  2019-04-01       Impact factor: 7.196

9.  The many facets of the matricelluar protein periostin during cardiac development, remodeling, and pathophysiology.

Authors:  Russell A Norris; Ricardo Moreno-Rodriguez; Stanley Hoffman; Roger R Markwald
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

10.  Incidence and mortality trend of congenital heart disease at the global, regional, and national level, 1990-2017.

Authors:  Weiliang Wu; Jinxian He; Xiaobo Shao
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.